This site uses cookies.
Some of these cookies are essential to the operation of the site,
while others help to improve your experience by providing insights into how the site is being used.
For more information, please see the ProZ.com privacy policy.
English (monolingual) Spanish (monolingual) German to Portuguese Portuguese to English German to English English to German Portuguese to German German (monolingual)
This person has a SecurePRO™ card. Because this person is not a ProZ.com Plus subscriber, to view his or her SecurePRO™ card you must be a ProZ.com Business member or Plus subscriber.
Affiliations
This person is not affiliated with any business or Blue Board record at ProZ.com.
Open to considering volunteer work for registered non-profit organizations
Rates
Spanish to Portuguese - Rates: 0.03 - 0.05 USD per word / 10 - 15 USD per hour / 0.20 - 0.30 USD per audio/video minute Portuguese to Spanish - Rates: 0.03 - 0.05 USD per word / 10 - 15 USD per hour / 0.20 - 0.30 USD per audio/video minute Portuguese - Rates: 0.03 - 0.05 USD per word / 10 - 15 USD per hour / 0.20 - 0.30 USD per audio/video minute English - Rates: 0.03 - 0.05 USD per word / 10 - 15 USD per hour / 0.20 - 0.30 USD per audio/video minute Spanish - Rates: 0.03 - 0.05 USD per word / 10 - 15 USD per hour / 0.20 - 0.30 USD per audio/video minute
German to Portuguese - Rates: 0.03 - 0.05 USD per word / 10 - 15 USD per hour / 0.20 - 0.30 USD per audio/video minute Portuguese to English - Rates: 0.03 - 0.05 USD per word / 10 - 15 USD per hour / 0.20 - 0.30 USD per audio/video minute German to English - Rates: 0.03 - 0.05 USD per word / 10 - 15 USD per hour / 0.20 - 0.30 USD per audio/video minute English to German - Rates: 0.03 - 0.05 USD per word / 10 - 15 USD per hour / 0.20 - 0.30 USD per audio/video minute Portuguese to German - Rates: 0.03 - 0.05 USD per word / 10 - 15 USD per hour / 0.20 - 0.30 USD per audio/video minute German - Rates: 0.03 - 0.05 USD per word / 10 - 15 USD per hour / 0.20 - 0.30 USD per audio/video minute
More
Less
Payment methods accepted
PayPal, MasterCard, Wire transfer, Bitcoin
Portfolio
Sample translations submitted: 1
English to Portuguese: Covid-19 Recearch General field: Medical
Source text - English INTRODUCTION
Coronavirus disease 2019 (COVID-19) is a newly emergent human disease caused by a
naturally arising, novel coronavirus—the severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2). The virus spreads easily from person to person through respiratory droplets,
and infection typically causes fever, loss of taste or smell, shortness of breath, a dry cough,
and/or other symptoms and complications associated with COVID-19. The ease with which
the virus spreads and the virus’s ability to be transmitted by asymptomatic individuals have
caused possibly the most severe worldwide infectious disease pandemic of the modern age.
More than 100,000 Americans died from COVID-19 within the first four months of the pandemic, contributing to more than 350,000 deaths worldwide in the same time period.
NIH is uniquely positioned to lead a swift, coordinated research response to this public health
crisis. By leveraging existing funding mechanisms and establishing new programs, NIH is
rapidly mobilizing the disbursement of emergency government funding to the biomedical
research community while still maintaining a scientifically rigorous review process and strong scientific stewardship to support the most promising and meritorious science in the face of
a public health emergency.
Researchers have already established—and will continue to build on—an immense
fundamental knowledge base on viruses and their effects on humans built from decades of
NIH-supported research. Leveraging the most modern technologies and techniques—as
well as a rich reservoir of existing diagnostics, prevention strategies, and treatment options
used to combat viruses—researchers are rapidly identifying characteristics of SARS-CoV-2
and human responses to infection to speed the development of sorely needed interventions
for COVID-19.
Translation - Portuguese INTRODUÇÃO
A doença coronavírus 2019 (COVID-19) é uma doença humana emergente causada por um coronavírus
naturalmente surgido, o novo coronavírus - a síndrome respiratória aguda grave coronavírus 2 (SARS-CoV-2).
O vírus se espalha facilmente de pessoa para pessoa através de gotículas respiratórias, e a infecção
geralmente causa febre, perda de gosto ou cheiro, falta de ar, tosse seca e/ou outros sintomas e
complicações associados à COVID-19. A facilidade com que o vírus se espalha e a capacidade do vírus de
ser transmitido por indivíduos assintomáticos tem causado possivelmente a mais grave pandemia mundial de
doenças infecciosas da era moderna. Mais de 100.000 americanos morreram de COVID-19 nos primeiros
quatro meses da pandemia, contribuindo para mais de 350.000 mortes no mundo inteiro no mesmo período
de tempo.
O NIH está numa posição única para liderar uma resposta rápida e coordenada de pesquisa a esta crise de
saúde pública. Ao alavancar os mecanismos de financiamento existentes e estabelecer novos programas, o
NIH está mobilizando rapidamente o desembolso de fundos governamentais de emergência para a
comunidade de pesquisa biomédica, enquanto ainda mantém um processo de revisão cientificamente
rigoroso e uma gestão científica rigorosa para apoiar a ciência mais promissora e meritória em face de uma emergência de saúde pública.
Os pesquisadores já estabeleceram - e continuarão a estabelecer - uma imensa base de conhecimento
fundamental sobre vírus e seus efeitos sobre os seres humanos, construída a partir de décadas de pesquisa
apoiada pelo NIH. Alavancando as mais modernas tecnologias e técnicas - bem como um rico reservatório de
diagnósticos existentes, estratégias de prevenção e opções de tratamento utilizadas para combater os vírus -
os pesquisadores estão identificando rapidamente as características do SARS-CoV-2 e as respostas
humanas à infecção para acelerar o desenvolvimento de intervenções extremamente necessárias para a
COVID-19.
More
Less
Experience
Years of experience: 2. Registered at ProZ.com: Apr 2023.
Expertise